Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)

NCT00216294 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00216294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
April 30, 2006
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obsessive compulsive disorder (ocd)